Acute Coronary Syndrome clinical trials at University of California Health
2 in progress, 1 open to eligible people
Milvexian in Participants After a Recent Acute Coronary Syndrome
open to eligible people ages 18 years and up
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
at UCLA UCSD
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
Sorry, in progress, not accepting new patients
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug,
at UCLA
Last updated: